Equis ISSN 2398-2977

Firocoxib

Contributor(s): Adam Auckburally, Ruth Morgan

Introduction

Name

  • Firocoxib.

Class of drug

  • Non-stroidal anti-inflammatory drug.
  • Coxib class.

Description

Chemical name

  • 3-(Cyclopropylmethoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one.

Molecular formula

  • C17H20O5S.

Molecular weight

  • 336.402 g.

Physical properties

  • Solution for injection is clear and colorless, containing 20 mg/ml firocoxib.
  • Oral paste is white to off-white.
  • Each gram contains 8.2 mg firocoxib.

Storage requirements

  • Below 30°C; brief excursions up to 40°C are reported to be acceptable.
  • Solution for injection should be discarded after 1 month of opening.
  • Syringe for oral administration should be discarded after 3 months of opening.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • Licensed in the UK for alleviation of pain and inflammation in horses suffering from osteoarthritis and associated lameness.
  • Could potentially be used for other inflammatory condition off-license.
  • Its administration must be justified using the Cascade.
  • Has been shown to have good ocular penetration superior to flunixin meglumine Flunixin meglumine.
  • Firocoxib has been shown to have less effect on mucosal recovery following bowel ischemia, compared to flunixin; it is also a good visceral analgesic, therefore it may be useful following colic surgery.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmacokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

  • Do not administer with other NSAIDs or corticosteroids Therapeutics: anti-inflammatory drugs.
  • May compete for protein binding sites with diuretics, other NSAIDs and other highly protein bound drugs. This may lead to increased plasma concentrations of free drug and toxic effects. Other reported examples of highly protein bound drugs which may be displaced are - oral anticoagulants, glucocorticoids, sulfonamides Therapeutics: sulfonamides, methotrexate Methotrexate, valproic acid and phenytoin Phenytoin.
  • Concurrent administration of other nephrotoxic drugs should be avoided.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references from PubMed and VetMedResource.
  • Knych H K et al (2014) Detection and pharmacokinetics of three formulations of firocoxib following multiple administrations to horses. Equine Vet J 46 (6), 734 PubMed
  • Hilton H G et al (2011) Distribution of flunixin meglumine and firocoxib into aqueous humor of horses. J Vet Intern Med 25 (5), 1127-1133 PubMed.
  • Koene M et al (2010) Field trial validation of the efficacy and acceptability of Firocoxib, a highly selective COX-2 inhibitor, in a group of 96 lame horses. J Eq Vet Sc 30 (5), 237-243 VetMedResource.
  • Back W, MacAllister C G & van Heel M C V et al (2009) The use of force plate measurements to titrate the dosage of a new COX-2 inhibitor in lame horses.Equine Vet J 41 (3), 309-312 PubMed.
  • Cook V L, Meyer C T, Campbell N B & Blikslager A T (2009) Effect of firocoxib or flunixin meglumine on recovery of ischemic-injured equine jejunum. Am J Vet Res 70 (8), 992-1000 PubMed.
  • Dutton D W, Lashnits K J & Wegner K (2009) Managing severe hoof pain in a horse using multimodal analgesia and a modified composite pain scale. Equine Vet Educ 21 (1), 37-43 Wiley.
  • Doucet M Y, Bertone A L, Hendrickson D et al (2008) Comparison of efficacy and safety of paste formulations of firocoxib and phenylbutazone in horses with naturally occurring osteoarthritis. JAVMA 232 (1), 91-97 PubMed.
  • Letendre L T, Tessman R K, McClure S R et al (2008) Pharmacokinetics of firocoxib after administration of multiple consecutive daily doses to horses. Am J Vet Res 69 (11), 1399-1405 PubMed.
  • McConnico R S, Morgan T W, Williams C C, Hubert J D & Moore R M (2008) Pathophysiologic effects of phenylbutazone on the right dorsal colon in horses. Am J Vet Res 69 (11), 1496-1505 PubMed
  • Kvaternick V, Pollmeier M, Fischer J et al (2007) Pharmacokinetics and metabolism of orally administered Firocoxib, a novel second-generation coxib, in horses. J Vet Pharm Ther 30 (3), 208-217 PubMed.

Other sources of information

  • Plumb D C (2011) Veterinary Drug Handbook. 7th edn. Wiley-Blackwell, USA.
  • Hanson P D & Maddison J E (2008) Nonsteroidal anti-inflammatory drugs and chondroprotective agents. In: Small Animal Clinical Pharmacology. Eds: Maddison J E & Page S W & Church D B Saunders Elsevier, USA. pp 287-309.
  • Equioxx® (firocoxib) product information - Website: www.equioxx.com.

ADDED